Reply  by Burger, Andrew J
Both Dr. Moye´ and Dr. Annegers have been retained by counsel
as experts for the plaintiffs in ongoing fenfluramine litigation.
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REPLY
Phentermine and Fenfluramine (phen-fen) were popular medica-
tions for the treatment of obesity. After the Mayo clinic report (1),
numerous anecdotal reports and several small, nonrandomized
observational surveys (2) described significant, unsuspected cardiac
pathology in patients formerly on these drugs. Although the
methodology of these surveys differed, the prevalence of valvular
disease meeting the Food and Drug Administration case definition
for significant valvular regurgitation was similar in all five surveys
and ranged from 30 to 38% (overall: 32.8%). These findings
alarmed both the medical community and the general public.
There was a great concern that a “virtual epidemic” of valvular
disease was upon us.
In our study (3) only 18 subjects (8%) had significant valvular
regurgitation as defined by Food and Drug Administration criteria.
The most common finding was mild or greater aortic insufficiency
in 15 subjects and 3 subjects with moderate mitral regurgitation.
No subjects had severe regurgitation of any valve. The dose or
duration of medications did not appear to be significant.
Our study is just another piece of the puzzle; it is not the final
answer. Our data showed a much lower prevalence of valvular heart
disease. As stated in the article, our study has multiple limitations.
First, all subjects did not have an echocardiographic evaluation.
However, all patients were followed clinically. All patients were
asymptomatic; no new murmurs were found, and no subjects
underwent cardiac surgery. No significant clinical differences were
found between subjects who had echocardiograms performed and
those who did not. Our study could be biased to overestimate the
prevalence of valve disease because subjects who returned for an
echocardiogram may have been concerned about a heart problem,
while those who did not return were not.
Second, our study noted the inherent inaccuracies that exist in
differentiating relatively mild degrees of valvular regurgitation, that
is, trace versus mild aortic regurgitation (since most studies to date
have found mild aortic regurgitation to be the problem). The
differentiation of trace from mild degrees of valvular regurgitation
is subjective and problematic, especially when trace is considered
normal and mild is considered a “disease.” Furthermore, it is very
important to distinguish between a clinical diagnosis and an
echocardiographic finding.
Third, heart valves degenerate over time and become “leaky.” A
significant proportion of healthy men and women have detectable
valvular regurgitation by color Doppler. This is not a disease, and
these subjects will probably never develop a clinical syndrome.
These valvular abnormalities represent age-related degenerative
changes. The Food and Drug Administration’s criteria for valvular
regurgitation are too narrow and arbitrary, and the case definition
for pathologic regurgitation needs to be modified and age-specific.
Fourth, our study did not have a control group. Our informal
comparison to the Framingham study (4) was done only to assist
the reader’s understanding of the prevalence of valvular regurgita-
tion in phen-fen users and in the normal population. After
reproducing Doctors Moye and Annegers’ analysis, we then used
our study population to estimate the expected prevalence of valve
disease based on the published Framingham data. We found the
prevalence ratio for mitral and aortic regurgitation to be 0.67 and
1.29, respectively. However, we found an error in their calculation
of the total expected prevalence, which should have been a
weighted average expected prevalence. With this correction, the
prevalence ratio for mitral and aortic regurgitation becomes 1.34
and 3.13, respectively (Table 1).
Finally, the true risk of diet drugs to cause pathologic valvular
regurgitation is still unknown. Initial reports suggested a possible
epidemic of valve disease with the prevalence up to 38% of users.
Our study questions the degree to which phen-fen therapy
contributes to valvular regurgitation. Long-term, prospective, ran-
Table 1. Adjusted Cardiac Valvulopathy Prevalences
Proportion in Patients in Burger’s Population
Expected Prevalence
Mitral Regurgitation Aortic Regurgitation
Age Men Women Total Men Women Men Women
26–39 0.034 0.144 0.178 0 0 0 0
40–49 0.071 0.303 0.374 0.003 0.009 0.017 0.007
50–59 0.053 0.224 0.277 0.016 0.01 0.042 0.021
60–69 0.012 0.052 0.064 0.024 0.023 0.127 0.068
70–83 0.001 0.004 0.005 0.112 0 0.144 0.169
.83 0.019 0.083 0.102 0.112 0 0.144 0.169
Expected Prevalence 0.004 0.006 0.008 0.025
Total Expected Prevalence 0.010 0.033
Observed Prevalence 0.013 0.066
Prevalence Ratio 1.33 2.01
Table 1 reports the contribution of each gender-age category from Burger’s population to the expected prevalence. The expected
prevalence for each valve is computed and compared with the observed prevalence in Burger’s population.
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domized, controlled investigations with a sufficient number of
patients are needed. However, the general public and the medical
community should be reassured by our study that the severity of
the problem is probably much less than initially thought.
Andrew J. Burger, MD
BI Deaconess Medical Center
Harvard Medical School
Boston, Massachusetts 02215
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Risk of Neutropenia With Clopidogrel
Dr. Berger et al. presented a cogent comparison of ticlopidine and
clopidogrel after intracoronary artery stent placement (1). How-
ever, they present misleading information regarding the side effects
of clopidogrel. They state, “Clopidogrel does not cause neutrope-
nia . . . ” (1). The authors use the CAPRIE trial as a supporting
reference. In the CAPRIE trial “ . . . the numbers for low neutro-
phil counts were ten (0.10%) and 16 (0.17%) (clopidogrel and
aspirin groups, respectively). Among these latter cases, the neu-
trophil count fell below 0.45 3 10ˆ9/L for five (0.05%) and four
(0.04%) patients in the clopidogrel and aspirin groups, respective-
ly., . . . In CAPRIE, there was no excess neutropenia in the
clopidogrel group (2).” Hence, more appropriately, the authors
should have stated that the risk of neutropenia is less than with
ticlopidine but essentially equivalent to aspirin.
It is important for cardiologists to remember that clopidogrel
can be associated with neutropenia, albeit very infrequently.
Robert S. Dieter, MD
University of Wisconsin
Section of Cardiovascular Medicine
Department of Medicine
600 Highland Avenue
Madison, Wisconsin 53792
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REPLY
We appreciate Dr. Dieter’s interest in our article and the oppor-
tunity to respond to his letter. Patients in CAPRIE were inten-
sively monitored for neutropenia, and severe neutropenia (,450
per microliter) was observed in six patients, four of whom were
receiving clopidogrel (three women, one man, all of whom were
Caucasian). Although these patients did develop neutropenia while
receiving clopidogrel, we disagree with Dr. Dieter’s conclusion that
clopidogrel “caused” the neutropenia in these patients. One patient
was receiving chemotherapy for a malignancy when the neutrope-
nia occurred. Two patients developed only transient neutropenia,
which did not resume after clopidogrel was reinitiated, and they
continued to receive clopidogrel for the duration of the study. We
should mention that a fifth clopidogrel patient was described in the
CAPRIE manuscript as having developed neutropenia but was
found to have aplastic anemia and was, therefore, not considered
by the Food and Drug Administration to have developed “neutro-
penia.” This fifth clopidogrel patient does not appear in the
labeling for clopidogrel. (Similarly, two additional aspirin patients
were described in the CAPRIE manuscript as having developed
neutropenia; one had actually developed acute myelogenous leu-
kemia, and one was found to have been neutropenic at study
entry.)
Despite the “association” between clopidogrel and neutropenia
in these four patients, we are no more convinced that clopidogrel
caused their neutropenia than we are convinced that aspirin caused
the neutropenia in the two patients in the aspirin group. It is
important to distinguish between the frequency of “background”
Table 1.
Mitral Regurgitation Aortic Regurgitation
Age Men Women Men Women Men Women
26–39 0.186 0.142 0 0 0 0
40–49 0.302 0.361 0.003 0.009 0.017 0.007
50–59 0.442 0.383 0.016 0.01 0.042 0.021
60–69 0.07 0.115 0.024 0.023 0.127 0.068
70–83 0 0 0.112 0 0.144 0.169
.83 0 0 0.112 0 0.144 0.169
Expected prevalence 0.010 0.010 0.033 0.018
Total expected prevalence 0.010 0.021
Observed prevalence 0.013 0.066
Prevalence ratio 1.34 3.13
95% confidence limits 0.41–4.35 0.99–9.85
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